TW205037B - - Google Patents

Download PDF

Info

Publication number
TW205037B
TW205037B TW079107912A TW79107912A TW205037B TW 205037 B TW205037 B TW 205037B TW 079107912 A TW079107912 A TW 079107912A TW 79107912 A TW79107912 A TW 79107912A TW 205037 B TW205037 B TW 205037B
Authority
TW
Taiwan
Prior art keywords
compound
item
keto
methyl
alkyl
Prior art date
Application number
TW079107912A
Other languages
English (en)
Chinese (zh)
Original Assignee
Takeda Pharm Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharm Industry Co Ltd filed Critical Takeda Pharm Industry Co Ltd
Application granted granted Critical
Publication of TW205037B publication Critical patent/TW205037B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Holo Graphy (AREA)
  • Detergent Compositions (AREA)
  • Measurement Of Radiation (AREA)
TW079107912A 1989-10-06 1990-09-20 TW205037B (en:Method)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26278289 1989-10-06
JP32229089 1989-12-11

Publications (1)

Publication Number Publication Date
TW205037B true TW205037B (en:Method) 1993-05-01

Family

ID=26545706

Family Applications (1)

Application Number Title Priority Date Filing Date
TW079107912A TW205037B (en:Method) 1989-10-06 1990-09-20

Country Status (17)

Country Link
US (1) US5223513A (en:Method)
EP (1) EP0421456B1 (en:Method)
KR (1) KR910007883A (en:Method)
CN (1) CN1050715A (en:Method)
AT (1) ATE116301T1 (en:Method)
AU (1) AU629048B2 (en:Method)
CA (1) CA2026890C (en:Method)
DE (1) DE69015541T2 (en:Method)
FI (1) FI904915A7 (en:Method)
HU (1) HUT55364A (en:Method)
IE (1) IE903454A1 (en:Method)
IL (1) IL95839A (en:Method)
NO (1) NO904300L (en:Method)
NZ (1) NZ235582A (en:Method)
PT (1) PT95515A (en:Method)
RU (1) RU2001910C1 (en:Method)
TW (1) TW205037B (en:Method)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03181465A (ja) * 1989-12-11 1991-08-07 Takeda Chem Ind Ltd キノリン誘導体
HUT65748A (en) * 1991-04-26 1994-07-28 Pfizer Process for producing 4-aryl-3(heteroarylureido)-quinoline derivatives and pharmaceutical preparations containing them
JP2668163B2 (ja) * 1992-01-23 1997-10-27 ファイザー インク. コレステロール血症および抗アテローム動脈硬化症薬としての4−アリール−3−(ヘテロアリールウレイド)−1,2−ジヒドロ−2−オキソ−キノリン誘導体
TW241258B (en:Method) * 1992-04-15 1995-02-21 Takeda Pharm Industry Co Ltd
BR9306421A (pt) * 1992-05-28 1998-09-15 Pfizer Novos derivados n-aril e n-heteroariluréia como inbidores da acilcoenzima a:colesterol aciltransferase (acat)
US5482967A (en) * 1992-09-04 1996-01-09 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
US5565472A (en) * 1992-12-21 1996-10-15 Pfizer Inc. 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents
NZ264063A (en) * 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
TW263498B (en:Method) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
US6133326A (en) 1994-08-31 2000-10-17 Pfizer Inc Compositions and methods for decreasing sebum production
US5843957A (en) * 1995-05-19 1998-12-01 Sumitomo Pharmaceuticals Company, Ltd. Naphthyridine derivatives
WO1999009983A1 (en) * 1997-08-28 1999-03-04 Bristol-Myers Squibb Company 4-aryl-3-aminoquinoline-2-one derivatives as potassium channel modulators
US6300500B1 (en) 1998-02-25 2001-10-09 Sumitomo Pharmaceuticals Company, Limited Preparation of pyridone derivatives using phthalimido containing starting material
US6452008B2 (en) 1998-02-25 2002-09-17 Sumitomo Pharmaceuticals Company, Limited Pyridone derivatives and process for preparing the same
CZ20011965A3 (cs) * 1998-12-04 2001-09-12 Bristol-Myers Squibb Company Derivát v poloze 3 substituovaného 4-arylchinolin-2-onu jako modulátor draslíkového kanálku
PL357041A1 (en) * 2000-02-02 2004-07-12 Warner-Lambert Company Dual inhibitors of cholesteryl ester and wax ester synthesis for sebaceous gland disorders
CA2439663C (en) * 2001-03-02 2012-04-03 Sumika Fine Chemicals Co., Ltd. Process for producing quinoline-3-carboxylic acid compound
CZ20032898A3 (cs) * 2001-04-30 2004-07-14 Pfizer Products Inc. Způsob výroby inhibitorů CETP
WO2005030792A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Quinoline potassium channel inhibitors
EA201490846A1 (ru) * 2011-11-04 2014-07-30 Ф.Хоффманн-Ля Рош Аг Новые производные арилхинолина

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1216878B (de) * 1963-04-02 1966-05-18 Cassella Farbwerke Mainkur Ag Verfahren zur Herstellung von coronargefaesserweiternden Derivaten des 7-Hydroxy-2-oxo-1, 2-dihydrochinolins
NO133758C (en:Method) * 1970-04-04 1976-06-23 Takeda Chemical Industries Ltd
JPS555502B1 (en:Method) * 1971-07-31 1980-02-07
US4530931A (en) * 1983-01-03 1985-07-23 Usv Pharmaceutical Corp. 8-Quinoline carbanilates for the inhibition of lipolysis
EP0166354B1 (en) * 1984-06-26 1992-08-05 Merck & Co. Inc. Benzofused lactam compounds and pharmaceutical compositions containing them
IE892088L (en) * 1988-07-12 1990-01-12 William Henry Deryk Morris Quinoline derivatives, their production and use

Also Published As

Publication number Publication date
IE903454A1 (en) 1991-04-10
PT95515A (pt) 1991-08-14
ATE116301T1 (de) 1995-01-15
AU629048B2 (en) 1992-09-24
CN1050715A (zh) 1991-04-17
NO904300L (no) 1991-04-08
NZ235582A (en) 1992-03-26
FI904915A7 (fi) 1991-04-07
JPH03223254A (ja) 1991-10-02
DE69015541D1 (de) 1995-02-09
US5223513A (en) 1993-06-29
CA2026890A1 (en) 1991-04-07
AU6370790A (en) 1991-04-11
HUT55364A (en) 1991-05-28
RU2001910C1 (ru) 1993-10-30
EP0421456B1 (en) 1994-12-28
HU906360D0 (en) 1991-04-29
IL95839A (en) 1995-03-15
CA2026890C (en) 2001-09-18
DE69015541T2 (de) 1995-06-01
KR910007883A (ko) 1991-05-30
IL95839A0 (en) 1991-06-30
FI904915A0 (fi) 1990-10-05
EP0421456A3 (en) 1991-05-29
NO904300D0 (no) 1990-10-03
EP0421456A2 (en) 1991-04-10

Similar Documents

Publication Publication Date Title
TW205037B (en:Method)
KR880002232B1 (ko) 퀴놀린 유도체와 그 염의 제조방법
US5539119A (en) Indole derivatives
EP2705032B1 (en) Dihydroquinoline derivatives as bromodomain inhibitors
US4788186A (en) 6-substituted-s-triazolo[3,4-a]phthalazine derivatives
SK27096A3 (en) Carbocyclic and heterocyclic fused-ring quinolinecarboxylic acids and pharmaceutical composition on their base
EP0179383A2 (en) 9-Amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds, a process for their preparation and their use as medicaments
AU2007326449A1 (en) Carboxylic acid derivative
TW201103943A (en) Urea derivative having pi3k inhibitory activity
EP0104522B1 (en) New pyrazolo(3,4-b)pyridine derivatives and process for producing them
KR100488095B1 (ko) 1H-피리도(3,4-b)인돌-4-카르복사미드 유도체, 그의 제법 및치료에의 응용
TWI249533B (en) Pyridazin-3-one derivatives and medicines containing the same
FR2537584A1 (fr) Pyrazoloquinoleines substituees particulieres, procede pour leur preparation, preparations pharmaceutiques contenant ces composes et leur application therapeutique
JPS60161970A (ja) ジベンズアゼピン‐6‐オン化合物
JPH06763B2 (ja) ベンゾ〔h〕シンノリン誘導体
JPH05222002A (ja) 1位にエーテル基又はチオエーテル基を含有するフタラジン及び該化合物の製造方法、並びに該化合物を含有する、鎮痛性、消炎性、鎮痙性及び解熱作用を有する医薬及びその製造方法
TW384285B (en) Pharmaceutical composition containing quinoline or quinazoline derivatives and novel derivatives therefor
JP2000508299A (ja) 抗ウイルス作用を有する置換キノリン誘導体
CN114174270B (zh) 吡嗪-2(1h)-酮类化合物的a晶型和b晶型及其制备方法
TW462964B (en) Guanidine derivatives for the treatment and prevention of disorders caused by inhibiting hyperactivity of Na/H exchange transport system and process for producing the same
EP0107930A2 (en) Fused aromatic oxazepinones and sulphur analogues thereof and their preparation and use in counteracting histamine
US3753992A (en) Process and intermediates for quinine,quinidine and derivatives thereof
CN113166121B (zh) 一种fxr激动剂的固体形式、结晶形式、a晶型及其制备方法和应用
JPS5993047A (ja) 融合芳香族オキサゼピノン類およびそれらのイオウ類似体類
KR20030039372A (ko) 페녹시페닐 알칸술포네이트